Monopar Therapeutics Inc is a biotechnology company focused on developing novel cancer therapies aimed at improving patient outcomes
The company is engaged in the research and clinical development of unique drug candidates that target various forms of cancer, leveraging innovative approaches to enhance the efficacy and safety of treatments. Monopar's initiatives include optimizing pharmacological properties and exploring various combinations to maximize therapeutic benefits. By driving progress in oncology, Monopar Therapeutics aims to address significant unmet medical needs within the cancer treatment landscape.
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.
